Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment.

Preston RA, Mamikonyan G, Mastim M, Garg D, Kemper CJ, Xu A, Yeole R, Chavan R, Friedland HD, Bhatia A.

Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.00873-19. doi: 10.1128/AAC.00873-19. [Epub ahead of print]

PMID:
31332068
2.

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.

O'Donnell J, Preston RA, Mamikonyan G, Stone E, Isaacs R.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00794-19. doi: 10.1128/AAC.00794-19. Print 2019 Sep.

3.

Outcomes of minority patients with very severe hypertension (>220/>120 mmHg).

Preston RA, Arciniegas R, DeGraff S, Materson BJ, Bernstein J, Afshartous D.

J Hypertens. 2019 Feb;37(2):415-425. doi: 10.1097/HJH.0000000000001906.

PMID:
30520848
4.

Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.

Preston RA, Mamikonyan G, DeGraff S, Chiou J, Kemper CJ, Xu A, Mastim M, Yeole R, Chavan R, Patel A, Friedland HD, Bhatia A.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01484-18. doi: 10.1128/AAC.01484-18. Print 2019 Jan.

5.

Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.

Kosloski MP, Wang H, Pugatch D, Mensa FJ, Gane E, Lawitz E, Marbury TC, Preston RA, Kort J, Liu W.

Eur J Clin Pharmacol. 2019 Feb;75(2):217-226. doi: 10.1007/s00228-018-2576-4. Epub 2018 Oct 19.

PMID:
30341499
6.

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.

Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00326-18. doi: 10.1128/AAC.00326-18. Print 2018 Aug.

7.

Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry.

Yang S, Xu M, Lee EM, Gorshkov K, Shiryaev SA, He S, Sun W, Cheng YS, Hu X, Tharappel AM, Lu B, Pinto A, Farhy C, Huang CT, Zhang Z, Zhu W, Wu Y, Zhou Y, Song G, Zhu H, Shamim K, Martínez-Romero C, García-Sastre A, Preston RA, Jayaweera DT, Huang R, Huang W, Xia M, Simeonov A, Ming G, Qiu X, Terskikh AV, Tang H, Song H, Zheng W.

Cell Discov. 2018 Jun 5;4:31. doi: 10.1038/s41421-018-0034-1. eCollection 2018.

8.

Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.

Kosloski MP, Zhao W, Marbury TC, Preston RA, Collins MG, Pugatch D, Mensa F, Kort J, Liu W.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01990-17. doi: 10.1128/AAC.01990-17. Print 2018 Mar.

9.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment.

Marshall WL, Feng HP, Wenning L, Garrett G, Huang X, Liu F, Panebianco D, Caro L, Fandozzi C, Lasseter KC, Preston RA, Marbury T, Butterton JR, Iwamoto M, Yeh WW.

Eur J Drug Metab Pharmacokinet. 2018 Jun;43(3):321-329. doi: 10.1007/s13318-017-0451-9.

PMID:
29247332
10.

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.

Kusawake T, Kowalski D, Takada A, Kato K, Katashima M, Keirns JJ, Lewand M, Lasseter KC, Marbury TC, Preston RA.

Adv Ther. 2017 Dec;34(12):2612-2624. doi: 10.1007/s12325-017-0643-3. Epub 2017 Nov 13.

11.

Prehypertension is real and can be associated with target organ damage.

Materson BJ, Garcia-Estrada M, Degraff SB, Preston RA.

J Am Soc Hypertens. 2017 Nov;11(11):704-708. doi: 10.1016/j.jash.2017.09.005. Epub 2017 Sep 21. Review.

PMID:
28965768
12.

Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study.

Wang SX, Abramson SB, Attur M, Karsdal MA, Preston RA, Lozada CJ, Kosloski MP, Hong F, Jiang P, Saltarelli MJ, Hendrickson BA, Medema JK.

Osteoarthritis Cartilage. 2017 Dec;25(12):1952-1961. doi: 10.1016/j.joca.2017.09.007. Epub 2017 Sep 28.

13.

Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.

Dudkowski C, Karim A, Zhao Z, Alonso AB, Garg D, Preston RA.

J Clin Pharmacol. 2018 Jan;58(1):48-56. doi: 10.1002/jcph.970. Epub 2017 Jul 27.

14.

Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.

Horsmans Y, Zhou J, Liudmila M, Golor G, Shibolet O, Quinlan M, Emotte C, Boss H, Castro H, Sellami D, Preston RA.

Clin Pharmacokinet. 2018 Mar;57(3):345-354. doi: 10.1007/s40262-017-0560-2.

PMID:
28577129
15.

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.

Hoover R, Marbury TC, Preston RA, Quintas M, Lawrence LE, Paulson SK, Luke DR, Cammarata SK.

J Clin Pharmacol. 2017 Mar;57(3):328-335. doi: 10.1002/jcph.817. Epub 2016 Oct 14.

16.

Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.

Khatri A, Dutta S, Marbury TC, Preston RA, Rodrigues L Jr, Wang H, Awni WM, Menon RM.

Clin Pharmacokinet. 2017 Feb;56(2):153-163. doi: 10.1007/s40262-016-0429-9.

PMID:
27389403
17.

Hypertension in the frail elderly.

Materson BJ, Garcia-Estrada M, Preston RA.

J Am Soc Hypertens. 2016 Jun;10(6):536-41. doi: 10.1016/j.jash.2016.03.187. Epub 2016 Mar 26. Review.

PMID:
27118485
18.

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib.

Nguyen L, Holland J, Ramies D, Mamelok R, Benrimoh N, Ciric S, Marbury T, Preston RA, Heuman DM, Gavis E, Lacy S.

J Clin Pharmacol. 2016 Sep;56(9):1130-40. doi: 10.1002/jcph.714. Epub 2016 Mar 23.

PMID:
26865195
19.

Evidence for a gastrointestinal-renal kaliuretic signaling axis in humans.

Preston RA, Afshartous D, Rodco R, Alonso AB, Garg D.

Kidney Int. 2015 Dec;88(6):1383-1391. doi: 10.1038/ki.2015.243. Epub 2015 Aug 26.

PMID:
26308672
20.

Effects of nebivolol versus metoprolol on sodium sensitivity and renal sodium handling in hypertensive Hispanic postmenopausal women.

Preston RA, Afshartous D, Materson BJ, Rodco R, Alonso AB.

Hypertension. 2014 Aug;64(2):287-95. doi: 10.1161/HYPERTENSIONAHA.114.03476.

PMID:
24842917
21.

Reduction of proteinuria through podocyte alkalinization.

Altintas MM, Moriwaki K, Wei C, Möller CC, Flesche J, Li J, Yaddanapudi S, Faridi MH, Gödel M, Huber TB, Preston RA, Jiang JX, Kerjaschki D, Sever S, Reiser J.

J Biol Chem. 2014 Jun 20;289(25):17454-67. doi: 10.1074/jbc.M114.568998. Epub 2014 May 9.

22.

Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.

Lauring B, Li XS, Liu Y, Corr C, Lazarus N, Cote J, Larson P, Levonas AO, Lasseter KC, Preston RA, Smith WB, Lai E, Wagner JA.

J Clin Pharmacol. 2014 Nov;54(11):1247-55. doi: 10.1002/jcph.320. Epub 2014 Jun 6.

PMID:
24782116
23.

The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist.

Preston RA, Marbury TC, Wajima T, Graham S.

Am J Ther. 2015 May-Jun;22(3):171-81. doi: 10.1097/01.mjt.0000434044.39502.64.

PMID:
24413373
24.

Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment.

Preston RA, Karim A, Dudkowski C, Zhao Z, Garg D, Lenz O, Sica DA.

Clin Pharmacokinet. 2013 May;52(5):347-58. doi: 10.1007/s40262-013-0044-y.

PMID:
23575872
25.

How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?

Proschan M, Ford CE, Cutler JA, Graumlich JF, Pavlik V, Cushman WC, Davis BR, Alderman MH, Gordon D, Furberg CD, Franklin SS, Blumenthal SS, Castaldo RS, Preston RA; LHAT Collaborative Research Group.

Stat Med. 2013 Feb 28;32(5):884-97. doi: 10.1002/sim.5580. Epub 2012 Sep 7.

PMID:
22961832
26.

Sodium challenge does not support an acute gastrointestinal-renal natriuretic signaling axis in humans.

Preston RA, Afshartous D, Forte LR, Rodco R, Alonso AB, Garg D, Raij L.

Kidney Int. 2012 Dec;82(12):1313-20. doi: 10.1038/ki.2012.269. Epub 2012 Aug 8.

27.

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.

Krishna G, Ma L, Martinho M, Preston RA, O'Mara E.

J Antimicrob Chemother. 2012 Nov;67(11):2725-30. doi: 10.1093/jac/dks268. Epub 2012 Jul 24.

28.

Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.

Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA.

Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000.

PMID:
22799589
29.

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.

Statkevich P, Kosoglou T, Preston RA, Kumar B, Xuan F, Trusley C, Schiller JE, Langdon RB, Cutler DL.

Eur J Clin Pharmacol. 2012 Nov;68(11):1501-8. doi: 10.1007/s00228-012-1269-7. Epub 2012 Apr 19.

PMID:
22527342
30.

Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study.

Behm MO, Blanchard RL, Murphy MG, Palcza JS, Harris DE, Butterfield KL, Smith WB, Preston RA, Chodakewitz JA, Krucoff MW.

Headache. 2011 Jun;51(6):954-60. doi: 10.1111/j.1526-4610.2011.01901.x.

PMID:
21631478
31.

Gender differences in cardiac repolarization following intravenous sotalol administration.

Somberg JC, Preston RA, Ranade V, Cvetanovic I, Molnar J.

J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):86-92. doi: 10.1177/1074248411406505. Epub 2011 Apr 28.

PMID:
21527783
32.

QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol.

Somberg JC, Preston RA, Ranade V, Molnar J.

Cardiology. 2010;116(3):219-25. doi: 10.1159/000316050. Epub 2010 Aug 7.

PMID:
20693799
33.

Developing a safe intravenous sotalol dosing regimen.

Somberg JC, Preston RA, Ranade V, Molnar J.

Am J Ther. 2010 Jul-Aug;17(4):365-72. doi: 10.1097/MJT.0b013e3181ea3184.

PMID:
20562595
34.

Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis.

Dorr MB, Nelson AL, Mayer PR, Ranganath RP, Norris PM, Helzner EC, Preston RA.

Fertil Steril. 2010 Nov;94(6):2365-8. doi: 10.1016/j.fertnstert.2010.03.076. Epub 2010 May 13.

PMID:
20466363
35.

Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment.

Moton A, Krishna G, Ma L, O'Mara E, Prasad P, McLeod J, Preston RA.

Curr Med Res Opin. 2010 Jan;26(1):1-7. doi: 10.1185/03007990903364657.

PMID:
19886860
36.
37.

Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.

Preston RA, Afshartous D, Garg D, Medrano S, Alonso AB, Rodriguez R.

Hypertension. 2009 May;53(5):754-60. doi: 10.1161/HYPERTENSIONAHA.108.125252. Epub 2009 Mar 23.

PMID:
19307466
38.

Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Cushman WC, Ford CE, Einhorn PT, Wright JT Jr, Preston RA, Davis BR, Basile JN, Whelton PK, Weiss RJ, Bastien A, Courtney DL, Hamilton BP, Kirchner K, Louis GT, Retta TM, Vidt DG; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2008 Oct;10(10):751-60. doi: 10.1111/j.1751-7176.2008.00015.x.

39.

Recursive estimation method for predicting residual bladder urine volumes to improve accuracy of timed urine collections.

Afshartous D, Preston RA.

Stat Methods Med Res. 2009 Apr;18(2):119-30. doi: 10.1177/0962280207087726. Epub 2008 Apr 29.

PMID:
18445696
40.

Effects of selective vs. nonselective cyclooxygenase inhibition on dynamic renal potassium excretion: a randomized trial.

Preston RA, Afshartous D, Alonso AB.

Clin Pharmacol Ther. 2008 Aug;84(2):208-11. doi: 10.1038/clpt.2008.16. Epub 2008 Feb 27. No abstract available.

PMID:
18288080
41.

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Shue YK, Sears PS, Shangle S, Walsh RB, Lee C, Gorbach SL, Okumu F, Preston RA.

Antimicrob Agents Chemother. 2008 Apr;52(4):1391-5. doi: 10.1128/AAC.01045-07. Epub 2008 Feb 11.

43.

Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.

Karara AH, Hanes V, Alonso A, Ni P, Poola N, Silang R, Blode H, Preston RA.

J Clin Pharmacol. 2007 Oct;47(10):1292-302.

PMID:
17906162
44.

Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.

Noveck RJ, Preston RA, Swan SK.

Clin Pharmacokinet. 2007;46(6):525-34.

PMID:
17518511
45.
46.
47.

Extensive genomic plasticity in Pseudomonas aeruginosa revealed by identification and distribution studies of novel genes among clinical isolates.

Shen K, Sayeed S, Antalis P, Gladitz J, Ahmed A, Dice B, Janto B, Dopico R, Keefe R, Hayes J, Johnson S, Yu S, Ehrlich N, Jocz J, Kropp L, Wong R, Wadowsky RM, Slifkin M, Preston RA, Erdos G, Post JC, Ehrlich GD, Hu FZ.

Infect Immun. 2006 Sep;74(9):5272-83.

48.

Elevated platelet P-selectin expression and platelet activation in high risk patients with uncontrolled severe hypertension.

Preston RA, Coffey JO, Materson BJ, Ledford M, Alonso AB.

Atherosclerosis. 2007 May;192(1):148-54. Epub 2006 Jun 9.

PMID:
16764881
49.

Four mutations in Epidermodysplasia verruciformis 1 (EVER1) gene are not contributors to susceptibility in RRP.

Donfack J, Buchinsky FJ, Derkay CS, Steinberg BM, Choi SS, Conley SF, Meyer CM 3rd, McClay JE, Campisi P, Hu FZ, Preston RA, Abramson AL, Ehrlich GD, Post JC.

Int J Pediatr Otorhinolaryngol. 2006 Jul;70(7):1235-40. Epub 2006 Feb 17.

PMID:
16487602
50.

Characterization, distribution, and expression of novel genes among eight clinical isolates of Streptococcus pneumoniae.

Shen K, Gladitz J, Antalis P, Dice B, Janto B, Keefe R, Hayes J, Ahmed A, Dopico R, Ehrlich N, Jocz J, Kropp L, Yu S, Nistico L, Greenberg DP, Barbadora K, Preston RA, Post JC, Ehrlich GD, Hu FZ.

Infect Immun. 2006 Jan;74(1):321-30.

Supplemental Content

Loading ...
Support Center